TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A01:01 and A03:01 Plans to initiate Phase 1 study of both TSC-102 candidates in the second half of 2026 WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell re ...